Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has reported a robust growth for the first half of 2024, with a substantial increase in revenue by 32.2% and a dramatic rise in gross profit by 59.4% compared to the same period in 2023. The biopharmaceutical company also highlighted positive developments and breakthrough designations for their core product sac-TMT, which showed promising results in clinical trials for various cancers. The financial performance and clinical advancements signal a strong upward trajectory for the company’s future.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.